# Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer

> **NCT00217672** · PHASE2 · COMPLETED · sponsor: **Translational Oncology Research International** · enrollment: 76 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00217672
- **Lead sponsor:** Translational Oncology Research International
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2008-12
- **Final completion:** 2010-11
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2020-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00217672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00217672, "Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00217672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*